We therefore attempted to reduce reperfusion injury with a monoclonal antibody (MAb) to the complement component, C5a. In 13 control pigs and 9 pigs pretreated with this MAb, ischemia was induced by a 50-min occlusion of the left anterior descending coronary artery, followed by 3 h of reperfusion.
Infarct area (as percent of risk area) was reduced from 58 t 5% in controls to 38 2 7% (P < 0.05) in MAb-treated animals. Heart ratesystolic blood pressure product, left ventricular (LV) first derivative of pressure, LV end-diastolic pressure, and coronary blood flow were similar (P > 0.05) in the two groups. At 15 min of reperfusion, immunoreactive factor Bb began to increase significantly (P < 0.05) in regional coronary venous plasma, consistent with activation of the alternative complement pathway. The anti-C5a MAb did not attenuate formation of the membrane attack complex (C5b-9) as assessed by a hemolytic complement assay. Myocardial myeloperoxidase activity, a marker of tissue neutrophil concentration, was similar in the risk regions of the two groups, suggesting that neutrophi1 infiltration was unaltered by the MAb. However, in vitro the MAb (15 and 30 pg/ml) reduced Cfia-stimulated neutrophi1 aggregation (67.4 and 70.9%), chemotaxis (52.5 and 81.4%), degranulation (66.7 and 75.8%), and superoxide generation (26.7 and 100%) . In conclusion, myocardial infarctionreperfusion is associated with activation of the alternative complement pathway. Furthermore, a MAb to C5a that inhibits neutrophil cytotoxic activity, but neither the membrane attack complex nor myocardial neutrophil accumulation, decreases infarct size in pigs. These data suggest an important role of the alternative complement pathway and C5a in the propagation of ischemic cardiac damage during reperfusion.
anti-C5a antibody; complement; coronary blood flow; factor B; myeloperoxidase; neutrophils COMPLEMENT IS INTIMATELY involved in reperfusion injury following acute myocardial infarction. This concept is supported by several lines of investigation. Experimental studies demonstrating localization of the complement components Clq, C3, C4, and C5 in infarcted myocardium (29, 33) suggest that myocardial ischemia can activate the complement system (7, 29, 32) . Complement can promote tissue damage by both direct and indirect actions. The C5b-9 membrane attack complex, the terminal product of complement activation by either the classical or alternative pathways, has direct cytolytic activity (28, 40) and has been suggested in an in vitro model to induce myocardial injury (19) . Conversely, indirect tissue injury may be mediated by the actions of the anaphylatoxin, C5a, on neutrophils (6). In this regard, C5a, the most potent chemotactic component of the complement system (lo), stimulates a series of proinflammatory responses from neutrophils, including aggregation (1, 26) , plugging of the microcirculation (9), chemotactic migration (1, 26) , and release of cytotoxic products such as reactive oxygen metabolites and proteases (1, 26, 27) , processes that could contribute to reperfusion injury. The direct vasoconstrictive effects of the anaphylatoxins also may impair perfusion and augment ischemic injury (30) . Furthermore, inhibition or depletion of circulating complement decreases deposition of complement fragments and neutrophils in infarcted myocardium and reduces infarct size (29, 40) . Support for the importance of neutrophils in myocardial reperfusion injury is afforded by studies indicating limitation of infarct size by either depletion of circulating neutrophils (26, 27) or by pharmacological inhibition of neutrophil function (1, 26, 27) .
We have demonstrated that neutrophils are involved in the release of thromboxane, reduction of coronary blood flow, and impairment of contractile function produced by intracoronary infusion of both purified porcine C5a (12, 25, 37, 38) and zymosan-activated serum (ZAS; 38) in pigs. By contrast, [20] [21] [22] have reported that resident cardiac mast cells rather than circulating neutrophils release leukotrienes, as well as thromboxane, both of which mediate these C5a-induced cardiac actions. Our evidence supporting the role of neutrophils is derived from several lines of investigation. First, the cardiac effects of C5a are associated with neutrophil extraction from the coronary circulation (2, 25, 37, 38) . Second, a monoclonal antibody (MAb; IB4) directed against CDlS, the common P-chain of the white cell integrins, attenuates these C5a-induced cardiac effects (38) . In addition, a MAb to C5a inhibits its cardiac actions while preventing myocardial extraction of neutrophils (38) . These findings support the concept that cardiac derangements induced by exogenous C5a are partially dependent on neutrophil trapping by a CDl%mediated aggregation-adherence mechanism. Furthermore, these results suggest that inhibition of C5a activity has the potential to limit cardiac damage during myocardial infarction-reperfusion by attenuating C5a-induced neutrophil activation. Therefore, we evaluated the following hypotheses: 1) a MAb to porcine C5a reduces the extent of experimental myocardial infarction in pigs; and 2) the decrease in infarct size is associated with attenuation of C5a-induced neutrophil H449 activity as indicated by a reduction of neutrophil infiltration into ischemic tissue and in vitro inhibition of neutrophil cytotoxic activity.
METHODS

Instrumentation
Adult domestic pigs of either sex, weighing 16-35 kg, were preanesthetized with ketamine (20 mg/kg im), atropine (0.05 mg/kg im), and thiamylal sodium ( 10 mg/ kg iv). Animals were intubated and ventilated with positive pressure. After intubation, anesthesia was maintained with thiamylal sodium (lo-20 mg* kg-l l h-l).
The chest was opened by a midline sternotomy. into the left ventricle (LV). In seven animals, catheters were introduced into the left atrium and femoral artery for measurement of regional myocardial blood flow by the radioactive microsphere technique (17). The pericardium was opened, and the length of the left anterior descending coronary artery (LAD) was measured from the origin to the LV apex. The midpoint of the LAD was dissected free from surrounding tissue. Topical lidocaine was applied to the LAD during its dissection to reduce spasm. A nonocclusive catheter was placed in the anterior cardiac vein adjacent to the LAD midpoint.
Purified Porcine C5a and ZAS Porcine CSa was prepared from porcine ZAS by the method of Gerard and Hugli (16) . The purity of the polypeptide was established by amino acid analysis after acid hydrolysis.
ZAS was prepared as we have previously described (37) . Briefly, fresh pig blood was allowed to clot, centrifuged (2,000 g, 4°C 20 min), and the serum was frozen at -45°C. On the day before the experiment, the serum was thawed at room temperature and was incubated with zymosan (10 mg/ml; Sigma, St. Louis, MO) for 1 h at 37°C. and were recorded at each measurement period. The heart rate-blood pressure product was calculated by multiplying systolic arterial pressure and heart rate. After a 20-min period of stabilization following instrumentation, control data were recorded. MAb (0.5 mg/kg in 7 animals, 1.0 mglkg in 2 animals) was administered by intravenous infusion over 10 min. Blood samples were obtained for measurement of circulating MAb levels at control, 45 min of ischemia, and 1,2, and 3 h of reperfusion.
One group of control animals (n = 8) received either no intervention (n = 6) or intravenous infusion of MAb vehicle (PBS, n = 2). A second group of controls (n = 5) received the control MAb (0.5 mg/kg) by intravenous infusion over 10 min. Ten minutes after completion of infusion of MAb, vehicle, or the control MAb, hemodynamic variables and ECG were recorded and baseline regional myocardial blood flow was assessed in a subgroup of five control and three treated animals. The LAD was then occluded at its midpoint for 50 min by a nontraumatic occluder. Epicardial cyanosis was apparent in the area distal to the LAD occlusion in all animals. Hemodynamic data and ECG were recorded every 15 min during the period of occlusion. Radioactive microsphere blood flow measurements were repeated at 5 and 45 min during the period of occlusion. After 50 min, the occluder was removed, and the LAD was reperfused for 3 h while hemodynamic data were recorded every 30 min. During reperfusion, the color of the epicardium distal to the previously occluded site returned toward normal.
Blood flow measurements by microsphere injection were obtained at 45 and 180 min of reperfusion.
No parenteral pharmacological agents other than those indicated above were administered.
Direct current countershock (30 J) was applied to the epicardium [remote from the risk area (RA)] for sustained ventricular tachyarrhythmias associated with severe hypotension.
If hemodynamic stability was not restored within 3 min or if more than two shocks were required, the animal was excluded from the study.
In six of the eight control pigs and four additional pigs, coronary venous plasma samples (2.0 ml) were collected in iced test tubes containing EDTA and heparin before coronary ischemia, at 15 and 45 min after onset of occlusion, and 15,30, 60, 120, and 180 min after reperfusion for measurement of factor Bb to assess activation of the alternative complement pathway in this experimental model.
Measurement of Infarct Size
Myocardial infarct size was estimated by histochemical staining to identify normal, infarcted, and viable myocardium. After 3 h of reperfusion, the LAD was briefly reoccluded at the original site of occlusion, and 60 ml of 0.5% patent blue dye (Sigma) were injected into the left atrium to identify the region of myocardium at risk, indicated by absence of blue stain. Animals were then killed by ventricular fibrillation induced with electrical current (9 V) applied directly to the myocardium remote from the RA. Hearts were rapidly removed and rinsed, and the LV was sectioned into four to six transverse sections, w 1 cm thick, from apex to base. The slices were weighed and traced onto clear acetate sheets to demarcate the H450 DECREASED INFARCT SIZE BY ANTI-CSA ANTIBODY normal area (blue stain) and the RA (unstained). The slices were then incubated at 37°C in a 1% solution of triphenyltetrazolium chloride (TTC) in 10 mM potassium phosphate buffer (pH 7.4). After 20 min, the slices were removed from the TTC and retraced on the same acetate sheets to demarcate the area of myocardial salvage, indicated by red staining (TTC positive), within the RA. The tracings were magnified and scanned by computer (SigmaScan, Jandel Scientific, Corte Madera, CA) to yield the RA and infarct area (IA; unstained area within the RA) as a percent of slice weight, from which the estimated IA and RA were calculated for each heart. Total LV weight was obtained as the sum of the LV slice weights and the unsliced LV.
Regional Myocardial Blood Flow
Regional myocardial blood flow was assessed by injecting -3 x lo6 15-p m radiolabeled microspheres (New England Nuclear, Boston, MA) into the left atrium. Spheres were suspended in 10% dextran and 0.01% Tween 80 solvent and were agitated with a vortex mixer before injection. Radioisotopes used included 46Sc, g5Nb, l141n, lo3Ru, l13Sn, 51Cr, 141Ce, or 85Sr. Reference blood samples were withdrawn with a pump (Sage, model 351, C ambridge, MA) from the femoral artery catheter at 6 mllmin for 150 s. Regional myocardial and renal blood flows were calculated according to the method of Heymann et al. ( 17) . Myocardial and reference blood samples were analyzed for the quantity and energy level of gamma radiation using a germanium detector-based gamma counter (Micrad, Knoxville, TN). Regional myocardial blood flow (Q,) = Q;C,/ C,, where &r is the reference flow rate (ml/min), C, is the counts per minute from the myocardial tissue sample, and C, is the counts per minute from the reference blood sample. Blood flow was measured using tissue obtained from infarct, salvage, and normal myocardium identified by the staining techniques described in Measurement of Infarct Size. Myocardial blood flow was normalized for the weight of the tissue sample. Blood flows in the cortex and medulla of each kidney were also determined to document adequate mixing of the microspheres.
Mixing was confirmed if the difference in blood flow between right and left kidneys was < 15%. Blood flow data in the control group have been partially reported (1).
Myocardial
Myeloperoxidase (MPO) Activity
Several myocardial tissue samples in each pig were excised from the control, salvage, and infarct areas, frozen in liquid nitrogen, and stored at -45°C until assayed. MPO activity was measured as we have previously described (24) . Ice-cold, minced sections of myocardium were homogenized (10% wt/ vol) with a Polytron homogenizer (Brinkmann Instruments, Westbury, NY) in 50 mM phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethyl-ammonium bromide (HTAB) for 15 s (x2).
The homogenates were then sonicated for 15 s, and the supernatant containing the MPO enzyme was separated from the cellular debris by centrifugation at 20,000 g for 15 min (2°C). The appearance of a colored product from the MPOdependent reaction of o-dianisidine and hydrogen peroxide (0.0005%) was spectrophotometrically detected using 100 ~1 of supernatant and 1.9 ml of hydrogen peroxide and o-dianisidine in 50 mM PBS (pH = 6.0). Supernatant MPO activity was kinetically quantified on a temperature-controlled (25°C) spectrophotometer (Per-kin-Elmer, Lambda 3B, Ridgefield, CT) with a chart recorder. The absorbance at 460 nm was recorded for several minutes, and the change in absorbance over 1 min was measured during the linear portion (0.5-1.5 min) of the tracing. One unit of MPO activity was defined as that which degraded 1 mol hydrogen peroxide/min at 25°C. Assessment of this assay with isolated porcine neutrophils demonstrated a linear relationship (r = 0.92) between MPO and the number of cells such that 1 U of MPO activity correlated with 2.9 x lo6 neutrophils.
Histological
Assessment of Myocardial Neutrophil Distribution
After determination of infarct size, segments of myocardium were placed in buffered Formalin and processed for paraffin histology; tissue sections were stained with hematoxylin and eosin. The stained sections were examined at a magnification of x 100. The number of neutrophils per milhmeter squared in the interstium and in vessels in each section was determined in a blinded fashion by counting 25 random fields (0.01 mm2 each), which were averaged to give the number of neutrophils per millimeter squared. The ratio of neutrophils in vessels to interstitium was then calculated.
Neutrophil Isolation
Porcine neutrophils were isolated from venous blood as we have previously described ( 11). Briefly, heparinized pig blood was mixed with 4% gelatin, and red blood cells were allowed to sediment for 30 min at 37°C. Neutrophils were then isolated by Ficoll-Hypaque density gradient centrifugation of the neutroPhil-rich gelatin supernatant.
After being washed, the contaminating erythrocytes were removed by hypotonic lysis. The neutrophils were resuspended at a concentration of N 10 x lo6 cells/ml in modified Hanks' balanced salt solution (mHBSS). Preparations routinely contained > 96% neutrophils with > 95% viability, as assessed by trypan blue exclusion.
Neutrophil Degranulation
Polymorphonuclear leukocytes (PMN; 10 x lo6 cells/ml) were incubated in the presence and absence of C5a MAb (15 and 30 pg/ml, respectively) or vehicle for 15 min at 37°C. The cells were then incubated for 20 min at 37°C with C5a (final concentration 100 nglml) and cytochalasin B (5 pglml). After being cooled to 4°C and being centrifuged (2,500 g, 15 min), the cell-free supernatant was mixed (1:l) with 1% HTAB in 50 mM potassium phosphate buffer at pH 6.0 before sonication in an ice bath for 15 s. Suspensions were centrifuged, and the peroxidase activity of the resulting supernatants was measured as described above (Myocardial Myeloperoxidase Activity). A comparable aliquot of neutrophil (10 x 106/ml) served as the nonstimulated (100%) control.
Neutrophil Aggregation
CSa-induced neutrophil aggregation was studied with a modified platelet aggregometer (Chrono-Log, Havertown, PA) as we have previously described (38) . Briefly, after a preincubation period of 10 min at 37°C with either MAb or its vehicle (mHBSS), neutrophils (10 x 106/ml mHBSS) were placed in cuvettes (0.45 ml). After a 1-min preincubation period, Ca2+ and Mg2+ (1.0 and 0.5 mM final concentration, respectively) were added. Finally, C5a [lo0 rig/ml final concentration, prepared in 0.25% bovine serum albumin (BSA) in HBSS] was added to the neutrophil suspension, and the aggregation response was recorded as an increase in light transmission.
Neutrophil
Superoxide Anion Generation 
Neutrophil Chemotaxis
Porcine neutrophil chemotaxis was assessed utilizing a 48well microchemotaxis chamber and 3.0~pm pore polyvinylpyrollidine-free polycarbonate filter sheets (Costar, Cambridge, MA). PMN (0.5 x 106/ml) previously incubated for 10 min with MAb (15 and 30 pg/ml) or its vehicle (HBSS) were placed in the upper compartment of this chamber. The cells were separated from the lower compartment containing 5% ZAS or vehicle (HBSS) by the filter and were incubated for 30 min (5% COZ, 100% humidity, 37°C). After incubation, the cells that were adherent to the filters were fixed and stained. The number of cells migrating to the lower surface were then counted in 10 high-power (x400) fields, and the results were averaged.
Immunoreactive
Factor Bb Assay
In pilot studies, a murine MAb against human factor Bb (Quidel, San Diego, CA) was found to cross-react with porcine factor Bb in an immunoblot assay. The MAb did not react with any peptides in deproteinized [trichloroacetic acid (TCA)] pig serum. In contrast, the MAb did react with deproteinized ZAS. This MAb was used to develop an antibody-capture immunoassay. Coronary venous blood samples (2.0 ml) in 10 pigs collected during occlusion-reperfusion were deproteinized with 50 ~1 of 1.0 M TCA, and samples of the supernatant (100 ~1) were incubated in duplicate at 4°C for 18 h in 96-well microtiter plates (Corning, Corning, NY). A standard curve was constructed in duplicate with a range of 20 nglml to 200 Fg/ml purified human factor B (Quidel). After incubation, the plate was washed three times and then blocked with 350 ~1 of 5% BSA for 1.5 h at room temperature.
The plate was thoroughly emptied, and 50 ~1 of a MAb (1:500) against the human complement fragment Bb was incubated at room temperature for 1.5 h. The plate was washed three times, and 50 ~1 of a goat anti-mouse antibody (l:lO,OOO) labeled with peroxidase (Sigma) was incubated at room temperature for 30 min. The plate was washed three times and developed with 3,3',5,5'-tetramethyl benzidine dihydrochloride (Sigma). The plate was read at 650 nm with a microplate reader (Molecular Devices, THERMOmax, Menlo Park, CA). Sample values (rig/ml) were calculated from the standard curve with a log-logit curve using the SOFTmax software system (Molecular Devices).
Measurement of Mouse IgG (Anti-C5a MAb) in Pig Plasma
Venous blood samples (2 ml) were collected in heparinized syringes, centrifuged at 2,000 g for 15 min at 4"C, and the plasma was stored at -45°C until analyzed. The level of circulating MAb to C5a during the course of the ischemiareperfusion protocol was assessed by a standard enzymelinked immunosorbent assay, utilizing purified MAb as a standard. Briefly, 100~~1 aliquots of known concentrations of the MAb were used to coat the wells of a 96-well microtiter plate. Plasma to be analyzed for the presence of mouse MAb to C5a was also coated overnight at 4°C at 1: 10, l:lOO, and l:l,OOO dilutions in carbonate coating buffer. Thereafter, the plates were washed three times with PBS containing 0.05% Tween 20 (Sigma) and were then blocked with 1% BSA in PBS. Optimally diluted peroxidase-conjugated goat anti-mouse (100 ~1) antibody (Tago, Burlingame, CA) was then added to the well and incubated at room temperature for 1 h to detect the presence of mouse antibodies.
The plates were then washed three times with PBS containing 0.05% Tween 20 and were developed with 100 ~1 of 0.55 mg/ml2,2'-azino-bis(ethylbenzthiazoline-6-sulfonic acid) (Sigma) and 0.03% hydrogen peroxide. Color development was arrested by the addition of 100 ~1 of 0.5% sodium dodecyl sulfate after 10 min. All results were read at 405 nm. A standard curve was established in each plate, and the unknown concentrations were deduced from the linear portion of the standard curve.
Hemolytic Complement Assay (CH& The ability of anti-C5a
MAb to inhibit formation of the membrane attack complex was assessed by measurement of the effect of this MAb on the hemolytic activity of porcine serum (5). Briefly, porcine serum from four healthy domestic pigs was stored at -20°C until use. In each row of a 96-well round-bottom microtiter plate, serum was serially diluted in PBS to give a series of dilutions:
1 In two experiments, an aliquot of serum was incubated at 56°C for 1 h to denature the complement, and the serum was then serially diluted. With the plate on ice to retard activation, 50-~1 aliquots of antibody-sensitized sheep erythrocytes (Sigma) in gelatin-veronal buffer (1 x lo8 cells/ml) were added to each well and mixed. A negative control (cells + PBS) and a positive control (cells + distilled Hz01 were included in each row. The plate was incubated at 37°C for 30 min and was centrifuged for 10 min. Supernatants (50 ~1) were transferred to a flat-bottom plate and read at 405 nm on a microtiter plate reader. The percent hemolysis was calculated for each serum dilution and was converted to the term, log(y/l -y), where y = percent lysis, and was plotted against log( 1 /dilution) to yield a straight line from which the 50% hemolysis intercept was read (15). In this method, the CHsO is defined as the serum dilution giving 50% hemolysis of an equal volume of red blood cells. and was successful in restoring sinus rhythm in all cases.
Myocardial
Infarct Size
Infarct size (IA/RA) was similar in the two control groups (no therapy 60 -+ 9%, neutral antibody 56 t 5%). Therefore, they were combined to comprise a single control group (IA/RA 58 t 5%).
IA/RA was less (P < 0.05) in the group treated with the antX5a MAb (38 t 7%) than in the controls. RA as a percentage of total LV mass was similar in the controls and the animals treated with the antX5a MAb (Fig. 1 ).
Hemodynamic Function
There were no significant differences in hemodynamic data between the control and MAb groups at any of the measurement points during the control, occlusion, and reperfusion periods (Fig. 2) .
Regional sion (Table 1 ). There were no significant differences in regional myocardial blood flow in the RAs (salvage + infarcted regions) of the control and MAb-treated groups at the points measured during the control, occlusion, and reperfusion periods.
Myocardial MPO Activity and Neutrophil Distribution MPO activity was greater (P < 0.05) in the RA (salvage + infarct) than in the normal region of LV in both the control and MAb groups (Fig. 3) . However, there were no significant differences in MPO activity between the two groups in the respective normal and risk areas.
Tissue neutrophils in the myocardial risk region were preponderantly distributed in the interstitium, rather than within vessels, in both the control and treated animals. The ratio of neutrophils in vessels to intersti- tium was similar in the controls (0.27) and treated group These levels were comparable to those that inhibited (0.23).
C5a-induced responses of neutrophils in vitro (Table 2) .
Neutrophil Function Hemolytic Complement Assay (CH& The effects of MAb on neutrophil function in vitro are shown in Table 2 . At a concentration of 15 pg/ml, the MAb produced > 50% inhibition of aggregation, chemotaxis, and degranulation.
All neutrophil functions were reduced by > 70% at a MAb concentration of 30 kg/ml. Superoxide generation, which was least affected at the lower MAb concentration, was completely inhibited at the higher antibody concentration.
There were no significant differences in hemolysis of antibody-sensitized sheep erythrocytes by control serum and serum preincubated with the antiC5a MAb (Fig. 5) . By contrast, heat-inactivated serum demonstrated only minimal hemolytic activity. The CHsO for serum alone was 72 t 7, and for serum plus anti-C5a MAb it was 65 t 10 (NS).
DISCUSSION
Factor Bb Assay
Factor Bb was unchanged from control (221 t 58 rig/ml) during the ischemic period but was increased significantly at 15 min of reperfusion (P < 0.05) and remained elevated during the entire reperfusion period (Fig. 4) .
Anti-C5a MAb Plasma Levels
Plasma concentrations of MAb were between 18.2 t 1.4 and 20.4 t 0.7 pg/ml at the points measured (45 min of occlusion and 60, 120, and 180 min of reperfusion).
This study demonstrates that a MAb to the anaphylatoxin, C5a, limits myocardial infarct size in pigs. The cardioprotective action of this MAb was not associated with decreased infiltration of neutrophils into injured myocardium but was accompanied by in vitro attenuation of C5a-induced neutrophil aggregation, degranulation, and superoxide production, functions with proinflammatory and cytotoxic potential. In addition, our findings provide evidence for activation of the complement system by the alternative pathway during reperfusion, as reflected by the rise in factor Bb in coronary venous blood during this period. The complement hemolytic assay indicated that the antiC5a
MAb did not prevent generation of the C5b-9 membrane attack complex, which supports inhibition of C5a activity as the mechanism of cardioprotection. The absence of any effects of this MAb on hemodynamic function or coronary blood flow compared with controls indicates that its beneficial effects were not related to alteration of the major determinants of myocardial oxygen supply and demand. This study, therefore, is the first to provide evidence that experimental myocardial infarctionreperfusion injury 1) is associated with activation of the complement system by the alternative pathway and 2) can be limited by selective inhibition of the anaphylatoxin, C5a, by a MAb, most likely through attenuation of C5a-induced neutrophil activation. Complement-induced reperfusion injury associated with myocardial infarction has been attributed to the direct effects of the C5b-9 membrane attack complex and indirect actions mediated by the leukotactic properties of C5a. Recent experimental studies have extended prior evidence (7, 29, 32) tory injury by suppression of complement activation in rats with recombinant, soluble complement receptor type 1 (sCRl), an inhibitory regulator of complement. The protective effect of the inhibitor was associated with reduced deposition of C5b-9 on capillary endothelium and decreased myocardial accumulation of leukocytes, suggesting that both direct damage by the membrane attack complex and indirect injury related to anaphylatoxin-directed neutrophil activity were inhibited by sCR1.
In considering the mechanisms of the protective effect of the antiC5a MAb, it was essential to assess the influence of the MAb, which can cross-react with C5, on formation of the membrane attack complex. C5b-9 has been shown to produce direct myocardial injury in an isolated heart preparation (19). The CHSO assay measures in vitro hemolytic capacity of serum, which is related to generation of the membrane attack complex. The antiC5a MAb did not significantly inhibit formation of the membrane attack complex, as indicated by lack of an effect on hemolysis. These data suggest that reduction of infarct size with the antiC5a MAb was not related to an action on C5b-9. Thus, while there is evidence that the membrane attack complex may play a role in myocardial reperfusion injury (29, 40) , our findings suggest that C5a also significantly contributes to this process. Although the vasoconstrictive actions (30) and PMNrelated effects (12, 25, 37, 38) of C5a may contribute to its role in reperfusion injury, its direct effects on the myocardium appear to be limited. We have shown that purified porcine C5a has a biphasic, predominantly positive, but modest contractile action on isolated pig myocardium (2). Furthermore, Homeister et al. (19) were unable to reproduce the deleterious myocardial actions attributed to C5b-9 with C5a. However, the isolated rabbit heart preparation utilized by these investigators is limited by absence of ischemia and lack of neutrophils, two factors that are essential for anaphylatoxin-induced myocardial reperfusion injury. Prior studies support an interaction between C5a and neutrophils in reperfusion injury. Under the chemotactic and activating influence of C5a, neutrophils engage in a series of proinflammatory processes (1, 26, 27) (26, 27) or inhibition of their function by several methods (1, 26, 27) . [20] [21] [22] reported that resident cardiac mast cells rather than circulating neutrophils are the source of eicosanoids that mediate the deleterious cardiac effects of C5a. However, their studies relate only to intracoronary injection of exogenous C5a in nonischemic animals and thus may not be relevant to experimental myocardial infarction.
Our method of complement system inhibition to achieve a cardioprotective effect during myocardial ischemia-reperfusion differed from previous approaches (29, 40) . Our study involved selective inhibition of a single complement component and its des-Arg derivative (38) . By contrast, prior studies have been nonselective in regard to suppression (40) or depletion (29) 18, 34) . In this regard, we have demonstrated that the dual lipoxygenasecyclooxygenase inhibitor, BW755C, reduces infarct size in the pig in association with diminished production of cytotoxic mediators without reducing neutrophil infiltration of injured myocardium (1) . We assessed myocardial neutrophil content by measurement of tissue MPO activity. This method is based on the specificity of MPO as a marker for neutrophils (36) . The validity of tissue MPO activity as a measure of neutrophilcontent is supported by prior findings that demonstrate concordance between tissue MPO activity and histological determination of neutrophils in acutely infarcted myocardium (36) . Although neutrophils labeled with radioisotopes may provide more direct quantitative data, this method has the potential to significantly alter cellular integrity (31) .
It is possible that the protective effect of the anti-C5a MAb was related to prevention of neutrophil migration from the circulation into myocardial tissue, an effect that would not be detected by measurement of tissue MPO activity. However, histological analysis of myocardium from controls and animals treated with the antiC5a MAb revealed no difference in the distribution of intravascular and interstitial neutrophils in the two experimental groups. Prior studies have provided evidence that complement is involved in the cardiac damage produced during myocardial infarction. The complement components, Clq, C3, C4, and C5, have been identified in infarcted tissue (29, 33) , and inhibition of complement activity reduces infarct size (29, 40) . Our data provide the first direct evidence that the alternative pathway of the complement cascade is activated during myocardial infarction-reperfusion, as indicated by the rise of plasma factor Bb during the reperfusion phase. Activation of the alternate pathway results in cleavage of factor B, a serum protein specific to the alternative pathway, to factors Ba and Bb (23) . Elevation of plasma Bb concentration in the coronary venous effluent therefore indicates activation of the alternative pathway. Although we; measured factor Bb in the coronary venous effluent, our study allows no conclusions as to whether activation of the alternative pathway was primarily intra-or extravascular in origin. Rossen et al. (32) have reported that subcellular fragments released from ischemic, reperfused myocardium may activate complement in the interstitium, while intravascular activation of complement in infarction-reperfusion has been recently demonstrated (40) .
Several potential limitations of this study require consideration.
Our conclusions regarding the mechanism of the cardioprotective effect of the antiC5a MAb
